RARX - Ra Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue2,500-4,9284,094
Cost of Revenue----
Gross Profit2,500-4,9284,094
Operating Expenses
Research Development54,44945,25127,92815,217
Selling General and Administrative14,4399,7785,0242,233
Non Recurring----
Total Operating Expenses68,88855,02932,95217,450
Operating Income or Loss-66,388-55,029-28,024-13,356
Income from Continuing Operations
Total Other Income/Expenses Net1,426571-858-606
Earnings Before Interest and Taxes-66,388-55,029-28,024-13,356
Interest Expense----159
Income Before Tax-64,962-54,458-28,882-13,962
Income Tax Expense-19-19-18-19
Minority Interest----
Net Income From Continuing Ops-64,943-54,439-28,864-13,943
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-64,943-54,439-28,864-13,943
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-64,943-54,439-28,864-12,270